DNA Barcoding vs. HPTLC: Choosing the Right Botanical Identity Method for EU Supplement Exports

Something like 30% of the botanical materials traded internationally are adulterated — substituted, diluted, or misidentified at some point in the supply chain. That figure comes from the American Botanical Council’s Botanical Adulteration Prevention Program (BAPP), which has been systematically documenting the problem since 2012. For a European supplement manufacturer who’s built a quality system around EU Directive 2002/46/EC and their suppliers’ Certificates of Analysis, that number should be uncomfortable.

It’s not that European manufacturers don’t test. Most do. The issue is how they test — and whether those methods satisfy the regulators in the markets they’re actually selling into.

Two identity testing methods dominate the botanical testing space: High-Performance Thin-Layer Chromatography (HPTLC) and DNA barcoding. They answer different questions, they have different failure modes, and regulators in Europe, the United States, and Canada rely on them differently. Picking the wrong one for your product and your target market isn’t just a quality issue. It’s a regulatory exposure.

What HPTLC Actually Shows (and What It Misses)

HPTLC is the workhorse of botanical identity testing in Europe. The European Pharmacopoeia (Ph.Eur.) references HPTLC extensively — it’s the method of choice across hundreds of herbal monographs, and it’s what EMA’s Committee on Herbal Medicinal Products (HMPC) expects when they specify identity tests in Community Herbal Monographs. If you’re filing a Traditional Herbal Registration (THR) in the EU under Directive 2004/24/EC, you’re almost certainly using HPTLC or TLC to satisfy the identity requirements.

The method works by separating the chemical constituents of a botanical extract across a silica plate, producing a fingerprint of bands at characteristic Rf values. Compare that fingerprint against a reference material — a validated chromatogram from a confirmed authentic sample — and you can confirm the species or detect substitution. It’s visual, relatively fast (a trained analyst can run 18–24 samples per plate), and powerful enough to distinguish Valeriana officinalis from Valeriana wallichii, or to catch the substitution of Echinacea pallida for E. purpurea.

But HPTLC has real limits. The method depends on the chemical markers being present, detectable, and stable. Highly processed extracts — spray-dried powders, supercritical CO₂ extracts, heavily purified fractions — can lose the very fingerprint that makes identification possible. And for some botanical categories, the chemical markers in one species are simply too similar to another for HPTLC to discriminate reliably without additional methods.

A well-documented example: Ginkgo biloba extract. The marker compounds (flavone glycosides and terpene lactones) are sufficiently characteristic for HPTLC identification when the extract is fresh and standardised. But add fillers, maltodextrin, or partial hydrolysis, and the fingerprint becomes ambiguous quickly. We’ve seen samples arrive from suppliers with perfectly clean HPTLC profiles that were, on DNA analysis, shown to contain a significant proportion of undeclared material.

There’s also the cost-per-sample reality. A validated HPTLC analysis for a single botanical raw material in a GMP context typically runs €200–450 per sample at a qualified contract laboratory. Reasonable for a finished herbal medicinal product. For a manufacturer sourcing 20 botanical raw materials and testing every incoming lot, it adds up fast.

DNA Barcoding: The Method European Brands Keep Underestimating

DNA barcoding became practical for routine botanical testing around 2012–2014, when sequencing costs dropped dramatically and the international barcode libraries — primarily BOLD Systems and GenBank — accumulated enough authenticated reference sequences to make species identification meaningful. The technique works by amplifying and sequencing short, standardised regions of the plant genome — typically rbcL, matK, or the ITS2 spacer region — and comparing the result against a library of authenticated reference sequences.

The headline advantage is straightforward: DNA doesn’t care about processing conditions the way chemical markers do. If there’s plant material in your extract, there’s likely enough genomic DNA to amplify, even in a heavily concentrated or processed material. The 2015 BMC Medicine paper that caused genuine shockwaves in the industry found that 59% of herbal products sampled from major North American retailers contained species not declared on their labels — and DNA barcoding was the primary tool that uncovered the substitution.

But DNA barcoding has its own failure modes, and European brands adopting it without understanding them make different mistakes. For highly purified extracts where the manufacturing process includes harsh acid hydrolysis, steam distillation, or prolonged heat treatment, DNA may be too degraded to amplify reliably. There’s also the hybrid and cultivar problem: standard single-marker barcoding often cannot distinguish between closely related species or chemotypes that are phytochemically distinct but genetically very similar. Certain Panax species, Lavandula chemotypes, and the broader Cannabis genus are all cases where standard barcode sequences don’t provide enough resolution.

Another thing European manufacturers consistently miss: FDA’s expectations around DNA testing methods. The agency does not formally mandate DNA barcoding under 21 CFR 111.75 — but FDA guidance and USP General Chapter <2023>, “Identification of Articles of Botanical Origin”, specifically describes DNA-based methods as appropriate for identity verification, particularly where chemical testing alone is insufficient. The USP DNA Botanical Working Group has been publishing validated DNA barcode sequences since 2016. If you’re exporting supplements to the US market and your botanical identity SOP references HPTLC exclusively, you may be one FDA inspection observation away from a required programme expansion.

How Regulators on Both Sides of the Atlantic Treat These Methods Differently

This divergence in regulatory expectations is the practical problem for European exporters, and it’s more nuanced than most compliance guides acknowledge.

In the EU, the Ph.Eur. and HMPC monographs reference HPTLC as the primary identity method for the vast majority of herbal drugs. For products regulated as Traditional Herbal Medicinal Products (THMPs), HPTLC satisfies identity requirements. EFSA guidance on food supplements doesn’t prescribe identity methods directly — it defers to Ph.Eur. and internationally recognised pharmacopoeias for quality standards. A European manufacturer operating exclusively within the EU can build a fully compliant quality system around HPTLC and never encounter a DNA barcoding requirement.

In the United States, FDA’s cGMP regulations at 21 CFR Part 111 require identity testing on each lot of dietary ingredient before it can be used in manufacture. The regulation is method-neutral in its language — it says you must use “at least one test to identify the ingredient.” But FDA warning letters and 483 inspection observations consistently cite inadequate botanical identity testing, and the agency’s published guidance increasingly references USP <2023> and DNA methods. Critically, FDA has cited manufacturers for relying entirely on certificates of analysis from their own suppliers without conducting independent identity testing. That pattern — routine in European supply chains, particularly for ingredients sourced through multi-tier distribution — is a documented and recurring FDA compliance failure.

In Canada, Health Canada’s Natural Health Products Regulations (NHPR, SOR/2003-196) require that NHP site licence holders test each lot of raw material for identity before use in manufacture. Health Canada’s Quality of Natural Health Products Guide references both Ph.Eur. and USP methods as acceptable, and the Natural and Non-prescription Health Products Directorate (NNHPD) has accepted HPTLC identity data from EU laboratories — provided those labs can demonstrate ISO 17025 accreditation and the method is validated for the specific botanical material in question. DNA methods are accepted as supplementary or primary evidence when HPTLC is ambiguous or inappropriate for the product form.

The practical implication: a European manufacturer exporting to both the EU and North America may need to maintain capabilities for both methods, or work with a contract laboratory network that can. This isn’t just a cost question — it requires validated methods, authenticated reference standards, and qualified laboratory personnel. That combination isn’t routine at most European contract labs. It’s considerably more accessible through partner networks with accredited North American laboratory presence.

Choosing the Right Method for Your Product and Your Target Market

Rather than treating this as an HPTLC-versus-DNA debate, the pragmatic approach is to map your choice to your product form, your botanical category, and your target regulatory jurisdiction.

Use HPTLC as your primary method when:

• Your product is regulated as a THMP or food supplement in the EU and you’re not currently exporting to North America
• The botanical is present as a whole herb, a standardised extract, or a dried herbal drug — not a highly refined or hydrolysed fraction
• A Ph.Eur. monograph or HMPC Community Herbal Monograph exists and specifies HPTLC identity tests
• You need a method that provides chemical-class information alongside identity (HPTLC gives you approximate chemotype data; DNA barcoding does not)

Layer in DNA barcoding when:

• You’re exporting to the US under FDA 21 CFR Part 111 and the botanical is highly processed or presented in a complex matrix
• You’re exporting to Canada under the NHPR and working with botanically diverse raw materials where species substitution is commercially motivated — echinacea, ginseng, elderberry, turmeric, and ashwagandha are all BAPP-documented high-risk categories
• Your HPTLC fingerprint is ambiguous or your reference chromatograms are incomplete for the specific botanical variety or chemotype you’re sourcing
• Your supplier CoA is your only current identity evidence and you have limited visibility into their internal testing programme

The gold standard — increasingly what sophisticated US and Canadian buyers, contract manufacturers, and regulatory reviewers expect — is orthogonal testing: both methods applied to the same material. It costs more. A combined HPTLC and DNA barcoding analysis from a qualified laboratory typically runs €350–650 per botanical raw material per lot. But for a high-risk botanical — and the BAPP has published adulteration bulletins for over 40 species, including black cohosh, ashwagandha, turmeric, and milk thistle — that cost is modest against the cost of a recall, a regulatory action, or a supply chain fraud investigation.

European supplement brands entering North American markets tend to underestimate this layer of testing because their EU quality systems don’t require it. That’s the gap. Understanding which method your regulator expects, for which product form, in which jurisdiction, is the foundation of a compliant botanical identity programme — not a footnote in the quality manual.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• ISO 17025 Botanical Testing for US Market Entry — Qalitex Laboratories provides accredited HPTLC and DNA barcoding services for European brands shipping dietary supplements to the US market.
• Health Canada NHP Identity Testing for European Brands — Androxa offers Canadian GMP-compliant botanical identity testing for European supplement manufacturers pursuing NHP product licences.